Aspen Australia commenced operations in May 2001 with a portfolio of products generating sales of around $10 million. After the acquisition of the Sigma pharmaceutical business in February 2011, current annualised sales are close to $650 million in Australia and New Zealand. Aspen Australia is also responsible for a growing business in a dozen countries in Asia accounting with a projected $139 million in in-market sales for FY 2016.
Besides marketing and distributing products owned by the Aspen Group, we also license in products from other companies, and are focused on meeting the needs of our licensors.
We have 5 teams of sales representatives, who are all results-driven and experienced, covering doctors, specialists, hospitals, and pharmacists, plus we use an outsourced field force for grocery.
We are one of the largest pharmaceutical companies in Australia, and have one of the most comprehensive portfolios of medicine in the country, covering most disease states.